The clinical phenotype of wild-type, heterozygous, and homozygous JAK2 V617F in polycythemia vera

Cancer

Volumn 106, Issue 3, 2006, Pages 631-635

  Tefferi, Ayalew ^a   Lasho, Terra L ^a   Schwager, Susan M ^a   Strand, Jacob S ^a   Elliott, Michelle ^a   Mesa, Ruben ^a   Li, Chin Yang ^a   Wadleigh, Martha ^a   Lee, Stephanie J ^b   Gilliland, D Gary ^b  

^a MAYO CLINIC   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Heterozygotes; Homozygotes; JAK2V617F; Mutant allele; Myeloid cells; Polycythemia vera

Indexed keywords

JANUS KINASE 2; JANUS KINASE 2 V617F; UNCLASSIFIED DRUG;

ADULT; AGED; ALLELE; ARTICLE; BONE MARROW CELL; ERYTHROCYTOSIS; FEMALE; GENE MUTATION; HETEROZYGOSITY; HETEROZYGOTE; HIGH RISK PATIENT; HOMOZYGOSITY; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; POLYCYTHEMIA VERA; PRIORITY JOURNAL; WILD TYPE;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; DISEASE PROGRESSION; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; FEMALE; GRANULOCYTES; HEMOGLOBINS; HUMANS; ISOANTIGENS; JANUS KINASE 2; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; PHENOTYPE; POLYCYTHEMIA VERA; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; PRURITUS; RECEPTORS, CELL SURFACE;

EID: 31544477194     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.21645     Document Type: Article

References (14)

1. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365:1054-1061.
2. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythemia vera. Nature. 2005;434:1144-1148.
3. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352:1779-1790.
4. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7:387-397.
5. Zhao R, Xing S, Li Z, et al. Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem. 2005;280:22788-22792. Epub 2005 Apr 29.
6. Steensma DP, Dewald GW, Lasho TL, et al. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes. Blood. 2005;106:1207-1209. Epub 2005 Apr 28
7. Jones AV, Kreil S, Zoi K, et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood. 2005;106:2162-2168. Epub 2005 May 26.
8. Harris NL, Jaffe ES, Diebold J, et al. The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997. Ann Oncol. 1999;10:1419-1432.
9. Barosi G, Ambrosetti A, Finelli C, et al. The Italian Consensus Conference on Diagnostic Criteria for Myelofibrosis with Myeloid Metaplasia. Br J Haematol. 1999;104:730-737.
10. Reeder TL, Bailey RJ, Dewald GW, Tefferi A. Both B and T lymphocytes may be clonally involved in myelofibrosis with myeloid metaplasia. Blood. 2003;101:1981-1983.
11. Tefferi A, Lasho TL, Brockman SR, Elliott MA, Dispenzieri A, Pardanani A. FIP1L1-PDGFRA and c-kit D816V mutation-based clonality studies in systemic mast cell disease associated with eosinophilia. Haematologica. 2004;89:871-873.
12. Tefferi A, Lasho TL, Wolanskyj AP, Mesa RA. Neutrophil PRV-1 expression across the chronic myeloproliferative disorders and in secondary or spurious polycythemia. Blood. 2004;103:3547-3548.
13. Yoon SY, Li CY, Mesa RA, Tefferi A. Bone marrow effects of anagrelide therapy in patients with myelofibrosis with myeloid metaplasia. Br J Haematol. 1999;106:682-688.
14. Goerttler PS, Steimle C, Marz E, et al. The Jak2V617F mutation, PRV-1 overexpression and EEC formation define a similar cohort of MPD patients. Blood. 2005;106:2862-2864.